13-Mar-2026
GoodRx to offer up to 85% discount on Viatris drugs
Seeking Alpha News (Wed, 11-Mar 10:07 AM ET)
GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications
Business Wire (Wed, 11-Mar 9:00 AM ET)
GoodRx to Expand Employer-Sponsored Access to Zepbound KwikPen
Business Wire (Fri, 6-Mar 9:00 AM ET)
GoodRx Expands Into Employer Market With Launch of "GoodRx Employer Direct"
Business Wire (Tue, 24-Feb 9:00 AM ET)
GoodRx Powers Pricing for Leading Brand Medications on TrumpRx
Business Wire (Thu, 5-Feb 7:44 PM ET)
Business Wire (Mon, 2-Feb 9:00 AM ET)
60 Degrees Pharmaceuticals Expands Access to ARAKODA with GoodRx Partnership
Globe Newswire (Mon, 2-Feb 8:01 AM ET)
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
Business Wire (Wed, 28-Jan 4:05 PM ET)
Surescripts and GoodRx Partner to Advance Patient Price Transparency
Business Wire (Tue, 13-Jan 8:00 AM ET)
GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies
Business Wire (Thu, 8-Jan 9:00 AM ET)
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Goodrx Holdings - Class A trades on the NASDAQ stock market under the symbol GDRX.
As of March 13, 2026, GDRX stock price climbed to $2.24 with 1,293,326 million shares trading.
GDRX has a beta of 0.85, meaning it tends to be less sensitive to market movements. GDRX has a correlation of 0.05 to the broad based SPY ETF.
GDRX has a market cap of $804.92 million. This is considered a Small Cap stock.
Last quarter Goodrx Holdings - Class A reported $195 million in Revenue and $.09 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.02.
In the last 3 years, GDRX traded as high as $9.37 and as low as $1.77.
The top ETF exchange traded funds that GDRX belongs to (by Net Assets): VTI, VB, VBR, VXF, CALF.
GDRX has underperformed the market in the last year with a return of -49.9%, while the SPY ETF gained +21.4%. In the last 3 month period, GDRX fell short of the market, returning -20.6%, while SPY returned -2.6%. However, in the most recent 2 weeks GDRX has outperformed the stock market by returning +19.8%, while SPY returned -3.5%.
GDRX support price is $2.09 and resistance is $2.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDRX shares will trade within this expected range on the day.
